AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_b7b30cb8-d8b8-47fb-a3cb-22dd94a33df6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: Arbuckle Stuart A (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 4356 | $210.39 | Disposed | 62500 | Direct |
| 2021-02-11 | Common Stock | S | 600 | $211.19 | Disposed | 61900 | Direct |
| 2021-02-11 | Common Stock | S | 200 | $212.10 | Disposed | 61700 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 140 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.39 (range $209.85 to $210.83).
F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.19 (range $210.86 to $211.66).
F5: Open market sales reported on this line occurred at a weighted average price of $212.10 (range $211.99 to $212.21).